Most conventional anticancer agents preferentially target rapidly growing tumor cells, i.e., those closest to perfused vessels, and may therefore augment the activity of TEM8 blocking therapies which target the nutrient-stressed compartment. This evidence concerns the gene ANTXR1 and neoplasm.